Rosetta Genomics and Meir Medical Center in Kfar Saba, Israel, will observe nonsmall cell lung cancer patients who were considered for treatment that would have used their immune systems to fight cancer.

Rosetta Genomics's RosettaGX Reveal, a molecular test for thyroid patients, was recently approved in New York, making the test available in all 50 states.

International pharmaceutical company Rosetta Genomics said in a March 20 release that it has been granted a patent allowance and moved a step closer to obtaining a patent for its thyroid cancer test.

Rosetta Genomics Ltd. of Princeton, New Jersey, a developer and provider of microRNA-based and other molecular diagnostics, recently received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/446,505, titled “Compositions and Methods for the Prognosis and Treatment of Prostate Cancer,” a patent that is designed to provide an effective prostate cancer treatment.